Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$6.37 USD

6.37
2,238,320

-1.28 (-16.73%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

New Strong Sell Stocks for August 21st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

    AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology

    AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.

      Why Is AngioDynamics (ANGO) Up 5.02% Since Its Last Earnings Report?

      AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day

        Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day

          Kevin Cook headshot

          Bear of the Day: AngioDynamics (ANGO)

          Small cap force in non-surgical alternatives for peripheral vascular disease hits a growth/valuation peak

            AngioDynamics (ANGO) Q4 Performance Dull, Competition Rife

            AngioDynamics' (ANGO) fourth-quarter performance dull; stiff competition a serious concern.

              AngioDynamics (ANGO) Misses Q4 Earnings & Revenue Estimates

              AngioDynamics (ANGO) misses Q4 earnings and revenue estimates; international sales high.

                AngioDynamics (ANGO) Misses Q4 Earnings and Revenue Estimates

                AngioDynamics (ANGO) delivered earnings and revenue surprises of -4.76% and -0.75%, respectively, for the quarter ended May 2018. Do the numbers hold clues to what lies ahead for the stock?

                  Q2 Earnings Season In Focus

                  Q2 Earnings Season In Focus

                    Mark Vickery headshot

                    What's Sparking Market Futures? Big Q2 Results

                    There is a bright, shining beacon markets appear to be attracted to currently: Q2 earnings season.

                      What's in Store for AngioDynamics (ANGO) in Q4 Earnings?

                      AngioDynamics' (ANGO) expanding product pipeline, international market expansion and cost-saving initiatives to provide growth opportunities in Q4.

                        Why Is AngioDynamics (ANGO) Up 13.9% Since Its Last Earnings Report?

                        AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          AngioDynamics (ANGO) Product Line Strong, Debt Level High

                          AngioDynamics (ANGO) rides on promising NanoKnife performance. Dwindling sales are a concern.

                            AngioDynamics (ANGO) Beats on Q3 Earnings, Reiterates View

                            AngioDynamics (ANGO) witnesses gross margin expansion and strong profits in the third quarter of fiscal 2018. However, lower sales in the company's RFA product line in Japan is a concern.

                              AngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer

                              AngioDynamics (ANGO) gets flagship NanoKnife designated with EAP.

                                AngioDynamics (ANGO) Banks on Buyouts, Debt Level High

                                AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.

                                  Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James

                                  Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James

                                    Bet on These 5 PEG-Ratio Based GARP Picks

                                    A lower PEG ratio, preferably less than one, is always better for GARP investors.

                                      AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2

                                      Dwindling revenues in two major segments hurt AngioDynamics' (ANGO) second-quarter results.

                                        Can AngioDynamics (ANGO) Pull a Surprise in Q2 Earnings?

                                        AngioDynamics (ANGO) to gain from solid product portfolio and demand for Solero MTA system. However, unfavorable estimates are a concern.

                                          Why Is AngioDynamics (ANGO) Up 5.3% Since the Last Earnings Report?

                                          AngioDynamics (ANGO) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            AngioDynamicis' (ANGO) Solero MTA System to Drive Growth

                                            Growth in the core Angiographic Catheter business is also likely to fortify the company's footprint in the global space.

                                              AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1

                                              AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.

                                                Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?

                                                AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.

                                                  AngioDynamics' BioFlo Platform Strong, Debt Levels High

                                                  AngioDynamics' (ANGO) exclusive Endexo technology in the BioFlo unit is expected to enhance the company's growth trajectory. However, high debt levels limit the company's core business strategies.